Skip to main content
Advertising

Originally published Thursday, May 23, 2013 at 1:42 PM

  • Share:
           
  • Comments (0)
  • Print

News Summary: J&J predicts surge of new medicines

BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones.

BIG IMPACT: Two experimental medicines could transform current treatments. One is an antidepressant that appears to work in just a day, instead of taking weeks. The other is a powerful painkiller that's not addictive.

BIG REBOUND: J&J has recovered from a sales drop in 2009, fueled by the launch of 11 new products since then. Last year, those drugs brought in about one-sixth of J&J's $25.4 billion in total pharmaceutical sales.

News where, when and how you want it

Email Icon

Want free career advice? And an iPad Mini?

Want free career advice? And an iPad Mini?

Tell us about your goals and challenges and be considered for a future NWjobs career-makeover story, as well as a chance to win an iPad Mini!

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►